^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    3d
    Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov)
    P3, N=400, Active, not recruiting, Novavax | Trial completion date: Mar 2024 --> Aug 2024
    Trial completion date
    3d
    Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 (clinicaltrials.gov)
    P1/2, N=74, Recruiting, Imunon | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease (clinicaltrials.gov)
    P3, N=12, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    3d
    Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations (clinicaltrials.gov)
    P2, N=120, Suspended, University of Wisconsin, Madison | Trial completion date: Sep 2024 --> Mar 2025 | Recruiting --> Suspended | Trial primary completion date: Sep 2024 --> Mar 2025
    Trial completion date • Trial suspension • Trial primary completion date
    3d
    Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, EuBiologics Co.,Ltd
    New P1 trial
    4d
    Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older (clinicaltrials.gov)
    P1/2, N=682, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed
    Trial completion
    4d
    Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years (clinicaltrials.gov)
    P=N/A, N=25, Active, not recruiting, Pfizer | N=66 --> 25
    Enrollment change
    4d
    IOV-LUN-202: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=170, Recruiting, Iovance Biotherapeutics, Inc. | Trial completion date: Dec 2026 --> Dec 2031 | Trial primary completion date: Jun 2024 --> Dec 2030
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    cyclophosphamide • LN-145
    4d
    VAT00002: Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (clinicaltrials.gov)
    P2/3, N=3385, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jun 2023 | Trial primary completion date: Jul 2024 --> Jun 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    4d
    Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2026 --> Oct 2027 | Initiation date: May 2024 --> Apr 2025 | Trial primary completion date: Nov 2026 --> Oct 2027
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide
    4d
    Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (clinicaltrials.gov)
    P1, N=159, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed
    Trial completion
    4d
    CVTB: Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients (clinicaltrials.gov)
    P=N/A, N=108, Enrolling by invitation, University of Oxford | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    5d
    Improvement of the Nuclease Resistance and Immunostimulatory Activity of CpG Oligodeoxynucleotides by Conjugation to Sugar-Immobilized Gold Nanoparticles. (PubMed, Bioconjug Chem)
    These results indicate that the sugar moiety on K3-SGNPs primarily functions as a hydrophilic dispersant for GNPs and the formulation of K3 to SGNPs contributes to improving the immunostimulatory activity of K3. Because our CpG ODN-SGNPs have superior induction activities for antigen-specific T-cell mediated immune responses, they may be effective adjuvants for vaccines and immunotherapies.
    Journal
    |
    TLR9 (Toll Like Receptor 9) • TLR7 (Toll Like Receptor 7)
    5d
    HEMONC CIRM IST Lung: CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR T790M • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Ad-CCL21-DC
    5d
    ARTEMIS-C: A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (clinicaltrials.gov)
    P1, N=243, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    5d
    A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (clinicaltrials.gov)
    P3, N=1480, Recruiting, CanSino Biologics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    5d
    TheraVACCS: Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (clinicaltrials.gov)
    P3, N=75, Active, not recruiting, University of Pretoria | Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: May 2023 --> May 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)
    5d
    Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, University Hospital Tuebingen | Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Viral vector
    6d
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=29, Completed, University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Sep 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    |
    Undisclosed mDC3/8-KRAS vaccine
    6d
    PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PANDA-VAC
    7d
    Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (clinicaltrials.gov)
    P1, N=140, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Terminated; Lack of product and funding.
    Trial termination
    7d
    A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (clinicaltrials.gov)
    P2, N=801, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    10d
    HVRRICANE: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Henry M. Jackson Foundation for the Advancement of Military Medicine | Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Feb 2025
    Enrollment closed • Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Cervarix (recombinant human papillomavirus bivalent vaccine)
    10d
    Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2030 --> Dec 2030 | Trial primary completion date: Oct 2028 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    neoantigen DNA vaccine
    10d
    A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents (clinicaltrials.gov)
    P3, N=750, Completed, Butantan Institute | Active, not recruiting --> Completed
    Trial completion
    10d
    Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, Grit Biotechnology
    New trial
    10d
    Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov)
    P1, N=300, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    10d
    Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (clinicaltrials.gov)
    P3, N=1200, Not yet recruiting, Shanghai Institute Of Biological Products
    New P3 trial • Head-to-Head
    10d
    Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults. (clinicaltrials.gov)
    P1, N=60, Completed, University of Saskatchewan | Active, not recruiting --> Completed
    Trial completion
    10d
    CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov)
    P3, N=2226, Not yet recruiting, Sanofi Pasteur, a Sanofi Company
    New P3 trial
    10d
    Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older (clinicaltrials.gov)
    P1/2, N=865, Active, not recruiting, Sanofi Pasteur, a Sanofi Company | Recruiting --> Active, not recruiting
    Enrollment closed • Lipid Nanoparticle
    11d
    Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. (PubMed, Mol Carcinog)
    In patients with incurable HPV16+ solid tumors treated with SQZ-PBMC-HPV, an increase in CD8+ T cell density within the tumor parenchyma was associated with superior disease control rate and overall survival. The product composition for patients with increased CD8+ T cell density was enriched for T cells.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • GZMB (Granzyme B)
    |
    HLA-A*02
    |
    SQZ-PBMC-HPV
    11d
    A Clinical Trial of COVAC-2 in Adults (clinicaltrials.gov)
    P2, N=150, Completed, University of Saskatchewan | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date
    12d
    DR-0201-ONC-001: A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=48, Recruiting, Dren Bio | Not yet recruiting --> Recruiting
    Enrollment open
    12d
    A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=117, Recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2025 --> May 2027 | Trial completion date: Nov 2026 --> May 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ezabenlimab (BI 754091) • BI 1831169
    12d
    A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above (clinicaltrials.gov)
    P3, N=850, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    12d
    A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above (clinicaltrials.gov)
    P3, N=850, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    12d
    A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, International AIDS Vaccine Initiative | Trial completion date: Jul 2023 --> Jul 2024
    Trial completion date
    |
    CD4 (CD4 Molecule)
    12d
    THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov)
    P1/2, N=60, Terminated, ImmunityBio, Inc. | N=180 --> 60 | Trial completion date: Sep 2023 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Mar 2024; Discontinued prior to enroll in Phase 2
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    12d
    A Study of the Effectiveness of Moderna COVID-19 Vaccine (clinicaltrials.gov)
    P=N/A, N=1000000, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Real-world evidence • Real-world
    13d
    DR-0201-ONC-001: A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Dren Bio
    New P1 trial
    13d
    RENOIR: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (clinicaltrials.gov)
    P3, N=45000, Recruiting, Pfizer | Active, not recruiting --> Recruiting | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date